MedTrace Logo

Malaria Challenge in Healthy Volunteers

NCT01500980 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2012-12-13

No results posted yet for this study

Summary

The purpose of this study is to determine if sterile, protective immunity to malaria can be induced by malaria parasite exposure limited to the early liver stage of the parasite lifecycle.

Conditions

Interventions

BIOLOGICAL

P. falciparum infection

P. falciparum (NF54 strain) infection delivered by the bites of 12 - 15 infected A. stephensi mosquitos

DRUG

Chloroquine

Weekly chloroquine dosing (600 mg loading dose, 300 mg thereafter)

DRUG

Primaquine

Primaquine (45 mg) on day 2 or 3 post ITV infection

DRUG

Primaquine

Primaquine (45 mg) on day 2 or 3 (pending results of pilot study) post ITV infection

Sponsors & Collaborators

  • Seattle Children's Hospital

    lead OTHER

Principal Investigators

  • Sara Healy, M.D. MPH · Seattle Biomedical Research Institution

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2012-07-31
Completion
2012-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01500980 on ClinicalTrials.gov